Venetoclax in AL amyloidosis- is this the beginning or the end?

AL Amyloidosis (AL) is a plasma cell disease marked by production and deposition of toxic free light chains in organs including the heart, kidney and nervous system. While treatment is generally borrowed from multiple myeloma (MM), patients typically have difficulty tolerating many of these drugs, namely the immunomodulatory drugs (IMiDs), due to high cardiac and hematologic toxicities. Recently daratumumab has been shown to be active in (AL), however for patients who become refractory to daratumumab, options remain bleak.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research